Coronary Artery Disease (CAD)
The purpose of this study is to test the safety of taking aspirin plus 3 months of a second blood thinner (antiplatelet) medicine [such as clopidogrel (Plavix), or prasugrel (Effient), or ticagrelor (Brilinta)] in people who have a SYNERGY stent.
Principal Investigator: Molly Szerlip, MD
Locations: Baylor Scott & White The Heart Hospital – Plano
Sponsor: Boston Scientific Corporation
IRB Number: 016-072
Trial Status: Enrolling
Exclusions: Adults only
Change in Care: Participating may change your care
EVOLVE: A prospective, multicenter, single-arm study designed to assess the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk for bleeding undergoing percutaneous coronary intervention (PCI) with a SYNERGYTM Everolimus-Eluting Platinum Chromium Coronary Stent.
Get Detailed Information On Clinicaltrials.gov »
Physicians are members of the medical staff at one of Baylor Scott & White Health's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor Scott & White The Heart Hospital – Plano or Baylor Scott & White Health.